22 May 2013
Keywords: Vernalis, Biogen Idec, Vipadenant, V2006/BIIBO14, Parkinson's disease
Article | 20 July 2010
UK drug developer Vernalis says that, along with its partner USA-based Biogen Idec, the companies will continue its novel A2 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
20 July 2010
21 July 2010
© 2013 thepharmaletter.com